Literature DB >> 31610732

Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.

Dejan Jakimovski1, Robert Zivadinov2, Murali Ramanthan3, Jesper Hagemeier4, Bianca Weinstock-Guttman5, Davorka Tomic6, Harald Kropshofer6, Tom A Fuchs4, Christian Barro7, David Leppert6, Özgür Yaldizli7, Jens Kuhle7, Ralph Hb Benedict5.   

Abstract

BACKGROUND: A limited number of studies investigated associations between serum neurofilament light chain (sNfL) and cognition in persons with multiple sclerosis (PwMS).
OBJECTIVE: To assess cross-sectional and longitudinal associations between sNfL levels, clinical, and cognitive performance in PwMS and age-matched healthy controls (HCs). MATERIALS: One hundred twenty-seven PwMS (85 relapsing-remitting MS/42 progressive MS), 20 clinically isolated syndrome patients, and 52 HCs were followed for 5 years. sNfL levels were measured using the single-molecule array (Simoa) assay and quantified in picograms per milliliter. Expanded Disability Status Scale (EDSS), walking, and manual dexterity tests were obtained. At follow-up, Brief International Cognitive Assessment for MS (BICAMS) was utilized. Cognitively impaired (CI) status was derived using HC-based z-scores. Age-, sex-, and education-adjusted analysis of covariance (ANCOVA) and regression models were used. Multiple comparison-adjusted values of q < 0.05 were considered significant.
RESULTS: In PwMS, sNfL levels were cross-sectionally associated with walking speed (r = 0.235, q = 0.036), manual dexterity (r = 0.337, q = 0.002), and cognitive processing speed (CPS; r =-0.265, q = 0.012). Baseline sNfL levels predicted 5-year EDSS scores (r = 0.25, q = 0.012), dexterity (r = 0.224, q = 0.033), and CPS (r =-0.205, q = 0.049). CI patients had higher sNfL levels (27.2 vs. 20.6, p = 0.016) and greater absolute longitudinal sNfL increase when compared with non-CI patients (4.8 vs. 0.7, p = 0.04).
CONCLUSION: Higher sNfL levels are associated with poorer current and future clinical and cognitive performance.

Entities:  

Keywords:  Multiple sclerosis (MS); cognition; longitudinal; neurofilament light chain; processing speed

Year:  2019        PMID: 31610732     DOI: 10.1177/1352458519881428

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  18 in total

1.  Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?

Authors:  Dejan Jakimovski; Ralph H B Benedict; Bianca Weinstock-Guttman; Osman Ozel; Tom A Fuchs; Norah Lincoff; Niels Bergsland; Michael G Dwyer; Robert Zivadinov
Journal:  J Neurol       Date:  2021-02-15       Impact factor: 4.849

2.  Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.

Authors:  Eleonora Virgilio; Domizia Vecchio; Ilaria Crespi; Chiara Puricelli; Paolo Barbero; Giulia Galli; Roberto Cantello; Umberto Dianzani; Cristoforo Comi
Journal:  J Neurol       Date:  2022-01-28       Impact factor: 4.849

3.  Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers.

Authors:  Tobias Brummer; Muthuraman Muthuraman; Falk Steffen; Timo Uphaus; Lena Minch; Maren Person; Frauke Zipp; Sergiu Groppa; Stefan Bittner; Vinzenz Fleischer
Journal:  Brain Commun       Date:  2022-07-08

Review 4.  Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Biomedicines       Date:  2022-05-06

5.  Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption.

Authors:  Kira Ashton; Tom A Fuchs; Devon Oship; Robert Zivadinov; Dejan Jakimovski; Niels Bergsland; Deepa P Ramasamy; Caila Vaughn; Bianca Weinstock-Guttman; Ralph H B Benedict; Michael G Dwyer
Journal:  J Neurol       Date:  2020-08-04       Impact factor: 4.849

6.  Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study.

Authors:  Eleonora Tavazzi; Dejan Jakimovski; Jens Kuhle; Jesper Hagemeier; Osman Ozel; Murali Ramanathan; Christian Barro; Niels Bergsland; Davorka Tomic; Harald Kropshofer; David Leppert; Zuzanna Michalak; Norah Lincoff; Michael G Dwyer; Ralph H B Benedict; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-18

7.  High serum neurofilament associates with diffuse white matter damage in MS.

Authors:  Maija Saraste; Svetlana Bezukladova; Markus Matilainen; Jouni Tuisku; Eero Rissanen; Marcus Sucksdorff; Sini Laaksonen; Anna Vuorimaa; Jens Kuhle; David Leppert; Laura Airas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-12-08

8.  Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia.

Authors:  Weibin Ma; Jingjing Zhang; Jialei Xu; Depeng Feng; Xiaoling Wang; Fengyu Zhang
Journal:  Dis Markers       Date:  2020-11-01       Impact factor: 3.434

9.  Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals.

Authors:  Jasmeer P Chhatwal; Aaron P Schultz; Yifan Dang; Beth Ostaszewski; Lei Liu; Hyun-Sik Yang; Keith A Johnson; Reisa A Sperling; Dennis J Selkoe
Journal:  Nat Commun       Date:  2020-11-27       Impact factor: 14.919

10.  Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis.

Authors:  Dejan Jakimovski; Niels Bergsland; Michael G Dwyer; Deepa P Ramasamy; Murali Ramanathan; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Diagnostics (Basel)       Date:  2020-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.